Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical leader advancing novel therapies for chronic hepatitis B through RNA interference and lipid nanoparticle delivery systems. This page provides investors and industry observers with timely updates on the company’s scientific progress, regulatory milestones, and strategic partnerships.
Access consolidated news coverage of ABUS’s clinical trials, patent developments, and collaborative research initiatives. Our repository includes press releases on drug candidate advancements, financial disclosures, and peer-reviewed study outcomes – all essential for tracking this innovator’s pursuit of HBV functional cures.
Key updates cover three critical areas: clinical-stage developments targeting viral suppression, technology licensing agreements leveraging proprietary LNP platforms, and research publications validating therapeutic approaches. Regular monitoring ensures you stay informed about ABUS’s role in reshaping infectious disease treatment paradigms.
Bookmark this page for direct access to verified updates from Arbutus Biopharma and third-party analyses. Check back frequently to track how ABUS’s dual focus on antiviral therapies and delivery technologies positions it within the competitive biopharmaceutical landscape.
Arbutus Biopharma (Nasdaq: ABUS) reported new clinical data from its Phase 1a/1b trial of AB-729, demonstrating significant safety and efficacy in treating chronic hepatitis B virus (HBV). The trial showed comparable declines in mean HBsAg levels with 60 mg doses administered every 4 weeks (–1.44 log10) and every 8 weeks (–1.37 log10, N=6). No serious adverse events were reported, reinforcing the drug's tolerability. The company aims to advance AB-729 into Phase 2a trials in 2021.
Arbutus Biopharma Corporation (Nasdaq: ABUS) released updated clinical data from its Phase 1a/1b trial of AB-729, an RNA interference therapeutic for chronic hepatitis B. The data showed significant declines in HBsAg with repeat 60 mg doses every 4 weeks, achieving a mean decline of -1.71 log10 IU/mL at week 20. A single 90 mg dose in HBV DNA positive subjects also resulted in meaningful reductions in HBsAg and HBV DNA. The company plans to advance AB-729 into Phase 2 combination studies, exploring less frequent dosing options. The product was reported to be safe and well tolerated.
Arbutus Biopharma Corporation (Nasdaq: ABUS) presented updated clinical data from its Phase 1a/1b trial of AB-729, a promising treatment for chronic hepatitis B infection. Key findings include a significant decline in HBsAg concentrations with repeat dosing of 60 mg every 4 weeks, showing further decline beyond week 12, with no plateau observed. AB-729 was generally safe and well tolerated, with expected decreases in HBV RNA and HBcrAg. A conference call is scheduled for November 16, 2020, to discuss these encouraging results further.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that CEO William Collier will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 12:35 pm EST. The company focuses on developing cures for chronic hepatitis B virus (HBV) infection and treatments for coronaviruses, including COVID-19. Attendees can access the live webcast through the company's website, with an archived replay available afterward. Arbutus continues to advance multiple drug candidates aimed at potentially curing chronic HBV.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported its third quarter 2020 financial results, highlighting progress in its Phase 1a/1b clinical trial for AB-729, an RNAi therapeutic for chronic hepatitis B virus (HBV). AB-729 showed significant reductions in HBsAg with a favorable safety profile. The company had cash reserves of $118.3 million, sufficient to fund operations into mid-2022. Despite a net loss of $21.8 million for the quarter, this is an improvement from the previous year's loss. The clinical collaboration with Assembly Biosciences is set to evaluate AB-729 in combination therapies.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced it will release its Q3 2020 financial results and corporate update on November 5, 2020. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Investors can access the live webcast through Arbutus' website, and a recorded version will be available afterward. The company focuses on developing a cure for chronic hepatitis B and treatments for coronaviruses, including COVID-19. For further details, visit www.arbutusbio.com.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced participation in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on October 20, 2020, at 10:00 am ET. The presenters include William Collier (CEO), Dr. Michael Sofia (CSO), Dr. Gaston Picchio (CDO), David Hastings (CFO), and Michael McElhaugh (CBO). The live webcast can be accessed on Arbutus' website, with an archived replay available post-conference. Arbutus is focused on developing a cure for chronic hepatitis B virus (HBV) infection and therapies for coronaviruses, including COVID-19.
Arbutus Biopharma (Nasdaq: ABUS) will participate in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on October 5, 2020, at 1:00 pm ET. Key presenters include President and CEO William Collier, Chief Scientific Officer Dr. Michael Sofia, Chief Development Officer Dr. Gaston Picchio, and Chief Financial Officer David Hastings. The event will be accessible via webcast on the company’s investor website, with a replay available after the conference. Arbutus focuses on developing a cure for chronic hepatitis B and therapies for coronaviruses, including COVID-19.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on October 5, 2020, at 1:00 pm ET. Key presenters include William Collier (President and CEO), Dr. Michael Sofia (Chief Scientific Officer), Dr. Gaston Picchio (Chief Development Officer), and David Hastings (Chief Financial Officer). The chat will be accessible via a live webcast on Arbutus' website, with an archived replay available post-conference. The company focuses on developing a cure for chronic hepatitis B and therapies for coronaviruses.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reports favorable results from ongoing Phase 1a/1b clinical trials for its RNAi drug AB-729 targeting chronic hepatitis B virus (HBV) infection. A single 90 mg dose showed a mean HBsAg reduction of 1.23 log10 IU/mL at week 12, indicating both efficacy and safety. The company continues to evaluate multiple dosing regimens, with results from 60 mg cohorts forthcoming. Over 250 million people are affected by HBV globally, showcasing a critical need for effective treatments.
